MRCK34.SA Merck & Co. Inc

Healthcare Pharmaceuticals Sao Paulo Exchange
103.50 BRL
Close of Nov 5, 2026
55.95 103.62
Market cap
BRL 2.04T
P/E
159.2x
P/B
8.54x
ROE
-26.6%
Dividend yield
1.44%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MRCK34.SA undervalued?

Graham number

The Graham number of Merck & Co. Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Merck & Co. Inc fundamental analysis

No fundamental analysis for Merck & Co. Inc yet.

Merck & Co. Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Merck & Co. Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccine…

Full company profile